Watching
EVH · Evolent Health, Inc
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on 21 October 2026; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A daily close below $3.75, which would put the shares back near the 1 October 2026 close of $3.39 and erase the rebound. The case also ends if the Q3 report withdraws the roughly 250 basis point Q4 medical expense ratio improvement or cuts 2026 adjusted EBITDA guidance below $120 million.
Not a pickResearch coverage at low conviction. A medium-or-higher call would open a pick on the scoreboard.
Catalyst (in 14 days)
How picks are graded →The thesis
Evolent Health's shares have rebounded to a $4.73 close on 14 October 2026 from $3.39 on 1 October 2026, but the recovery case is still unproven: the Q3 2026 report on 5 November 2026 decides whether management's guided Q4 medical-cost improvement and $120–135 million adjusted EBITDA range hold. The company confirmed that date and a before-market-open release in its own announcement on 9 October 2026.
The rebound arrived without a new company disclosure. The last operating update remains the 6 August 2026 Q2 report, and the 14-day relative strength index (RSI, a 0–100 momentum gauge) reads 78.9 on 14 October 2026, against 19.7 on 1 October 2026. The narrative is maturing: the story is well known, and the price has moved ahead of any new evidence since the 6 August 2026 report.
The shares remain 42.2% below the $8.18 52-week high and have fallen 18.6% over three months, per adjusted daily closes. Management guided Q3 medical costs higher before the improvement, so the report tests the second-half margin path, not the revenue line.
Bullish and bearish views on Evolent Health, Inc
The bull case on Evolent Health, Inc (EVH), in brief: Guidance was raised, not cut. The bear case: Growth is not producing profit.
Bull case
- Guidance was raised, not cut. The 6 August 2026 release lifted full-year 2026 revenue guidance to $2.6–2.7 billion from $2.4–2.6 billion and narrowed adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) to $120–135 million from $110–140 million. Q2 revenue was $652.5 million against roughly $598 million consensus.
- Management gave a dated margin path. On the 6 August 2026 call, management guided the medical expense ratio (MER, the share of revenue paid out as medical costs) higher in Q3 on a full quarter of the Highmark launch. It then guided about 250 basis points of improvement by Q4, toward a full-year 2026 target near 93%.
- A large oncology contract is queued. The oncology Performance Suite partnership covers 1.5 million lives across 11 states. Management projected about $300 million of annualized revenue on the 6 August 2026 call, with launch expected by December 2026 pending regulatory approvals.
- Analyst targets sit above the price. MarketBeat's consensus target is $5.96 as of 13 October 2026, with 11 buy, 4 hold and 1 sell ratings. J.P. Morgan and TD Cowen each moved to $6 from $5 (18 August 2026 and 17 August 2026), and Citigroup set $6 from $6.75 on 10 August 2026.
Bear case
- Growth is not producing profit. Q2 2026 revenue rose 46.9% while cost of revenue rose 66.2%. Adjusted EBITDA was $28.1 million, a 4.3% margin, against $37.5 million and 8.5% a year earlier.
- Medical costs run far above last year. Q2 2026 MER was 95.3% against 80.0% a year earlier. The roughly 93% full-year target needs a sharp second-half improvement that no report has yet shown.
- The balance sheet is thin against the debt. On 30 June 2026 Evolent held $115.7 million of cash and equivalents against $966.5 million of long-term debt, net. MarketBeat put the market value at $522.9 million on 13 October 2026.
- Analyst support is mixed. Truist cut its target to $6 from $7 with a hold rating on 12 August 2026. Canaccord Genuity raised to $7 with a buy on 21 July 2026, before the Q2 report.
Price setup
The adjusted close was $4.73 on 14 October 2026. The 52-week high is $8.18, and the 1 October 2026 close of $3.39 marks the recent low in the sources reviewed.
MarketBeat listed the 50-day moving average at $4.06 on 13 October 2026, so the shares now trade above it after spending September below it. The 14-day RSI of 78.9 on 14 October 2026 sits in the range generally read as overbought.
Crowding evidence is mixed. Momentum is stretched and the earnings date is 22 days away. No share issuance or new insider sale has been reported since 26 August 2026.
Catalysts, next 30 days
- 5 November 2026, before market open: Q3 2026 results, with a conference call at 8:30 a.m. ET, per Evolent's announcement dated 9 October 2026. The report shows whether the Q3 MER rise stays within guidance and whether the 250 basis point Q4 improvement and $120–135 million adjusted EBITDA range are kept.
- ~31 December 2026, est. (outside the window): Expected launch of the oncology Performance Suite partnership, pending regulatory approvals. A delay would remove a named growth source.
What would change the view
The case breaks if the Q3 report withdraws the roughly 250 basis point Q4 MER improvement, or if 2026 adjusted EBITDA guidance falls below $120 million. It also breaks if cost of revenue again grows faster than revenue while adjusted EBITDA falls year over year, or if a financing or covenant amendment appears in the report or a filing before it.
On price, a daily close below $3.75 would put the shares back near the 1 October 2026 close of $3.39 and show the rebound failed. A hold above the $4.06 50-day average through the report would be consistent with the rebound being absorbed.
A confirmed Q4 improvement with unchanged guidance would move the case from unproven to supported. The sample of one quarter after the Highmark launch is small, so a single report would not settle the margin trend.
What it trades with
Evolent's Performance Suite contracts carry medical-cost risk, so the shares respond to medical-cost trend commentary from managed care and value-based care companies. Q3 reports from those companies, due around Evolent's own date, can move the shares independently of Evolent's results.
Leverage links the shares to credit conditions. With $966.5 million of net long-term debt on 30 June 2026, financing news moves the equity more than it would for a net-cash company.
Notes
- Adjusted EBITDA excludes items included in generally accepted accounting principles results; the company's earnings releases provide the reconciliations.
- Performance Suite contracts carry medical-cost risk, so the medical expense ratio drives margin outcomes.
- Long-term debt, net was $966.5 million against $115.7 million of cash and equivalents on 30 June 2026.
Related · shared themes
HUM
Humana Inc.
Humana's 2027 Star Ratings put 95% of its Medicare Advantage members in 4-star-or-better plans, up from about 20%, restoring 2028 quality-bonus revenue; the 6 November third-quarter report shows whether 2026 costs stay inside guidance.
MCK
McKesson Corporation
McKesson's fast-growing oncology and specialty-drug business keeps lifting earnings above guidance; its 4 November 2026 report shows whether it raises the $44.20–$45.00 fiscal 2027 EPS outlook again.
LFST
LifeStance Health Group, Inc.
LifeStance Health can meet third-quarter adjusted-EBITDA guidance of $49–59 million without improving on its $66.0 million second quarter. The 5 November 2026 report shows whether that holds and whether the $215–235 million full-year outlook rises.
STLN
Starling Oncology, Inc.
Starling Oncology's shift to capitated cancer-care contracts is lifting gross profit faster than revenue; the third-quarter 2026 report, expected around 9 November–12, shows whether adjusted EBITDA lands in the guided $500,000–$1.5 million range with full-year guidance intact.